CTMX peer analysis
CytomX Therapeutics (CTMX) against its competitors: price, today's move, 1-year return and market value side by side.
CTMX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADAG Adagene | $2.51 | -6.34% | 30.73% | – |
| ADCT ADC Therapeutics | $1.53 | 2.68% | -66.95% | $195.33M |
| CLDX Celldex Therapeutics | $28.92 | -3.92% | 11.23% | $2.36B |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| NRIX Nurix Therapeutics | $25.77 | -3.84% | 101.64% | – |
| PYXS Pyxis Oncology | $1.81 | -4.23% | -47.08% | – |
| STRO Sutro Biopharma | $9.10 | -0.44% | -21.55% | $150.89M |
| VRXA Veraxa Biotech | $1.14 | 0.88% | – | – |
| XNCR Xencor | $29.65 | -0.57% | 109.84% | $2.22B |
| ZYME Zymeworks | $28.61 | 0.00% | 49.63% | $2.02B |
| CTMX CytomX Therapeutics | $2.34 | 2.18% | -29.73% | $509.88M |
- CTMX's peers: ADAG (Adagene), ADCT (ADC Therapeutics), CLDX (Celldex Therapeutics), MGNX (MacroGenics), NRIX (Nurix Therapeutics), PYXS (Pyxis Oncology), STRO (Sutro Biopharma), VRXA (Veraxa Biotech).
Updated 2026-11-02 17:14 UTC